The global asthma therapeutics market size accounted for US$ 26.84 billion in 2023 and is projected to reach around USD 45.28 billion by 2033, growing at a CAGR of 5.37% from 2024 to 2033.
Key Points
- North America dominated the market with the largest market share of 51% in 2023.
- Asia Pacific is observed to witness the fastest rate of growth during the forecast period.
- By drug class, the anti-inflammatory segment has contributed the largest market share of 63% in 2023.
- By drug class, the combination therapy segment is observed to witness a notable rate of growth during the forecast period.
- By product, the inhalers segment dominated the market in 2023.
- By route of administration, the inhaled segment recorded more than 47% of revenue share in 2023.
Report Summary
The global asthma therapeutics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the asthma therapeutics market across the globe.
A comprehensive estimate on the asthma therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of asthma therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3875
Asthma Therapeutics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 5.37% |
| Global Market Size in 2023 | USD 26.84 Billion |
| Global Market Size by 2033 | USD 45.28 Billion |
| U.S. Market Size in 2023 | USD 9.58 Billion |
| U.S. Market Size by 2033 | USD 16.16 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Drug Class, By Product, and By Route of Administration |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized asthma therapeutics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: UV LED Market Size to Cross USD 4,436.57 Million by 2033
Market Players
The report includes the profiles of key asthma therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Recent Developments
- In August 2023, The Phase II EXHALE-1 research results for dexpramipexole have been posted online in the Journal of Clinical Immunology and Allergy (JACI), according to a statement from Areteia Therapeutics, Inc. In individuals with eosinophilic asthma, the study aimed to assess the safety and effectiveness of dexpramipexole in reducing blood and airway eosinophilia.
- In January 2023, The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) gave AstraZeneca’s Tezspire a reasonable opinion for self-administration in pre-filled, single-use pens for patients with severe asthma who are 12 years of age and older. The very nature of the Type-II label variant allows for implementing the CHMP opinion without requiring a decision by the European Commission.
Key Market Players
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Sanofi.
- Koninklijke Philips N.V.
- BD
- Covis Pha
Segments Covered in the Report
By Drug Class
- Anti- inflammatory
- Bronchodilators
- Combination Therapy
By Product
- Inhalers
- Dry Powder
- Metered Dose
- Soft Mist
- Nebulizers
By Route of Administration
- Oral
- Inhaled
- Others
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Asthma Therapeutics Market
5.1. COVID-19 Landscape: Asthma Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Asthma Therapeutics Market, By Drug Class
8.1. Asthma Therapeutics Market, by Drug Class, 2024-2033
8.1.1 Anti- inflammatory
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Bronchodilators
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Combination Therapy
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Asthma Therapeutics Market, By Product
9.1. Asthma Therapeutics Market, by Product, 2024-2033
9.1.1. Inhalers
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Nebulizers
9.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Asthma Therapeutics Market, By Route of Administration
10.1. Asthma Therapeutics Market, by Route of Administration, 2024-2033
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Inhaled
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Asthma Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.2. Market Revenue and Forecast, by Product (2021-2033)
11.1.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.2. Market Revenue and Forecast, by Product (2021-2033)
11.2.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Product (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Product (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.2. Market Revenue and Forecast, by Product (2021-2033)
11.3.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Product (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Product (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Product (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Product (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
Chapter 12. Company Profiles
12.1. Teva Pharmaceutical Industries Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. GSK plc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co., Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffmann-La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AstraZeneca
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Boehringer Ingelheim International GmbH
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Sanofi
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Koninklijke Philips N.V.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. BD
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Covis Pha
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
